Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: Impact of alternative methods of CD4 count modelling

European Journal of Epidemiology

Volumn 22, Issue 10, 2007, Pages 737-744

  Deuffic Burban, Sylvie ^a,b   Losina, Elena ^c   Wang, Bingxia ^c,d   Gabillard, Delphine ^a   Messou, Eugène ^e   Divi, Nomita ^d   Freedberg, Kenneth A ^c,d   Anglaret, Xavier ^a   Yazdanpanah, Yazdan ^b,f,g  

^a INSERM   (France)

^b IESEG School of Management   (France)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e Programme PAC CI   (Côte d’Ivoire)

^f CENTRE HOSPITALIER DE TOURCOING   (France)

^g UNIV LILLE   (France)

Author keywords

CD4 cell count; Highly active antiretroviral therapy; Opportunistic infections; Sub Saharan Africa; Time dependent variable

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE;

ADULT; AFRICA; ARTICLE; BACTERIAL INFECTION; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; COTE D'IVOIRE; DEATH; DISEASE SEVERITY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION;

EID: 34748902968     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-007-9175-5     Document Type: Article

References (21)

1. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
2. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med 1997;126:939-45.
3. Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004;36:1028-33.
4. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV. MMWR Recomm Rep 2002;51:1-55.
5. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. HIV Clin Trials 2001;2:493-554.
6. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30(Suppl 1):S29-65.
7. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003;17:575-84.
8. Badri M, Bekker LG, Orrell C, Pitt J, Cilliers F, Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines. AIDS 2004;18:1159-68.
9. Attia A, Huët C, Anglaret X, et al. HIV-1-related morbidity in adults, Abidjan, Côte d'Ivoire: A nidus for bacterial diseases. J Acquir Immune Defic Syndr 2001;28:478-86.
10. Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet 1999;353:1463-8.
11. Dabis F, Msellati P, Meda N, et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double blind placebo-controlled multicentre trial. Lancet 1999;353:786-92.
12. Seyler C, Anglaret X, Dakoury-Dogbo N, et al. Medium-term survival, morbidity and immunovirological evolution in HIV-infected adults receiving antiretroviral therapy, Abidjan, Cote d'Ivoire. Antivir Ther 2003;8:385-93.
13. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006;367:1981-9.
14. Losina E, Anglaret X, Yazdanpanah Y, et al. Impact of opportunistic diseases on chronic mortality in HIV-infected adults in Cote d'Ivoire. S Afr Med J 2006;96:526-9.
15. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004;364:1428-34.
16. Miller V, Sabin CA, Phillips AN, et al. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000;14:2129-36.
17. Yazdanpanah Y, Chêne G, Losina E, et al. Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts. Int J Epidemiol 2001;30:864-71.
18. Anglaret X, Dakoury-Dogbo N, Bonard D, et al. Causes and empirical treatment of fever in HIV-infected adult outpatients, Abidjan, Cote d'Ivoire. AIDS 2002;16:909-18.
19. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002;359:2059-64.
20. Seage GR 3rd, Losina E, Goldie SJ, Paltiel AD, Kimmel AD, Freedberg KA. The relationship of preventable opportunistic infections, HIV-1 RNA, and CD4 Cell counts to chronic mortality. J Acquir Immune Defic Syndr 2002;30:421-8.
21. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients living with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 2005;19:1299-308.